trial

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

SAN FRANCISCO and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing…

2 months ago
Serenity Medical Announces Clinical Publication of First Prospective Multicenter Trial of the River Stent, a Novel Venous Sinus Stent for Treating Idiopathic Intracranial Hypertension (IIH)Serenity Medical Announces Clinical Publication of First Prospective Multicenter Trial of the River Stent, a Novel Venous Sinus Stent for Treating Idiopathic Intracranial Hypertension (IIH)

Serenity Medical Announces Clinical Publication of First Prospective Multicenter Trial of the River Stent, a Novel Venous Sinus Stent for Treating Idiopathic Intracranial Hypertension (IIH)

HARRISON, N.Y., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Serenity Medical, a NeuroTechnology Investors (NTI) portfolio company dedicated to the treatment…

2 months ago
Southern Star Research Applauded by Frost & Sullivan for Delivering Comprehensive Clinical Trial Solutions and Its Competitive StrategiesSouthern Star Research Applauded by Frost & Sullivan for Delivering Comprehensive Clinical Trial Solutions and Its Competitive Strategies

Southern Star Research Applauded by Frost & Sullivan for Delivering Comprehensive Clinical Trial Solutions and Its Competitive Strategies

Southern Star sets itself apart in the CRO market through a unique combination of trust, operational advantages, deep industry expertise,…

2 months ago
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

February 11, 2025 17:30 ET  | Source: AnaptysBio, Inc. SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:…

2 months ago
GCCL Applauded by Frost & Sullivan for Ensuring Consistent, Reliable Clinical Trial Data in APACGCCL Applauded by Frost & Sullivan for Ensuring Consistent, Reliable Clinical Trial Data in APAC

GCCL Applauded by Frost & Sullivan for Ensuring Consistent, Reliable Clinical Trial Data in APAC

GCCL is committed to customer success, emphasizing quality control at every stage—from analysis consulting and sample processing to data management—ensuring…

2 months ago
GH Research to Provide Update on Phase 2b Trial with GH001 in TRDGH Research to Provide Update on Phase 2b Trial with GH001 in TRD

GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the…

3 months ago
Outlook Therapeutics Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMDOutlook Therapeutics Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Outlook Therapeutics Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Data presented at Hawaiian Eye and Retina 2025 MeetingResults confirmed that intravitreal ONS-5010 provided early and sustained anatomic improvements, with…

3 months ago
Persephone Biosciences Announces First Subject Enrolled in ARTEMIS Clinical Trial of New Infant SynbioticPersephone Biosciences Announces First Subject Enrolled in ARTEMIS Clinical Trial of New Infant Synbiotic

Persephone Biosciences Announces First Subject Enrolled in ARTEMIS Clinical Trial of New Infant Synbiotic

SAN DIEGO, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Persephone Biosciences Inc., a commercial company restoring and reinvigorating the human gut…

3 months ago
Concept Medical Announces First Patient Enrollment in the MAGICAL BTK IDE Trial, Launching its PAD Clinical Program in the United StatesConcept Medical Announces First Patient Enrollment in the MAGICAL BTK IDE Trial, Launching its PAD Clinical Program in the United States

Concept Medical Announces First Patient Enrollment in the MAGICAL BTK IDE Trial, Launching its PAD Clinical Program in the United States

TAMPA, Fla., Jan. 16, 2025 /PRNewswire/ -- Concept Medical Inc., a global pioneer in innovative drug delivery technology, is proud to…

3 months ago
Concept Medical Announces First Patient Enrollment in the MAGICAL BTK IDE Trial, Launching its PAD Clinical Program in the United StatesConcept Medical Announces First Patient Enrollment in the MAGICAL BTK IDE Trial, Launching its PAD Clinical Program in the United States

Concept Medical Announces First Patient Enrollment in the MAGICAL BTK IDE Trial, Launching its PAD Clinical Program in the United States

TAMPA, Fla., Jan. 16, 2025 /PRNewswire/ -- Concept Medical Inc., a global pioneer in innovative drug delivery technology, is proud to…

3 months ago
Show more Posts
Show previous Posts